Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending August 2014. The report serves as a notification of transactions involving Directors, Persons Discharging Managerial Responsibility (PDMR), or Connected Persons, specifically regarding the GSK 401K plan.
Key Financial Metrics
The filing text does not provide revenue, profit, cash flow, margins, debt, or liquidity figures. The only financial data disclosed is the price of GSK American Depositary Shares (ADSs) used for a plan revaluation, which was $48.03 per ADS on August 1, 2014.
Material Changes
Following a revaluation of the cash element of the notional investment held within the GSK 401K plan, there was an increase in the notional allocation of ADSs on August 1, 2014. This change was notified to the registrant and specific individuals on August 4, 2014.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It is strictly a compliance notification under Disclosure and Transparency Rule 3.1.4R(1)(c).
Important Facts for Investors
- Transaction Type: Increase in notional ADS allocation within the GSK 401K plan due to revaluation.
- Valuation Date: August 1, 2014.
- Share Price: $48.03 per ADS.
- Individuals Affected: Dr. M. Slaoui (Director/PDMR) and Dr. K. Slaoui (Connected Person).
- Allocation Details: Dr. M. Slaoui received no additional ADSs; Dr. K. Slaoui received 5 ADSs.